112 related articles for article (PubMed ID: 34481006)
1. Simultaneous amelioration of diabetic ocular complications in lens and retinal tissues using a non-invasive drug delivery system.
Srinivasarao DA; Sreenivasa Reddy S; Bhanuprakash Reddy G; Katti DS
Int J Pharm; 2021 Oct; 608():121045. PubMed ID: 34481006
[TBL] [Abstract][Full Text] [Related]
2. Spatio-temporal control on the delivery of triamcinolone acetonide using polymeric nanoparticles reduces steroid induced cataract.
Srinivasarao DA; Reddy SS; Reddy GB; Katti DS
Int J Pharm; 2019 Sep; 568():118474. PubMed ID: 31279055
[TBL] [Abstract][Full Text] [Related]
3. A non-invasive nanoparticle mediated delivery of triamcinolone acetonide ameliorates diabetic retinopathy in rats.
Mahaling B; Srinivasarao DA; Raghu G; Kasam RK; Bhanuprakash Reddy G; Katti DS
Nanoscale; 2018 Sep; 10(35):16485-16498. PubMed ID: 29897081
[TBL] [Abstract][Full Text] [Related]
4. Episcleral drug film for better-targeted ocular drug delivery and controlled release using multilayered poly-ε-caprolactone (PCL).
Sun S; Li J; Li X; Lan B; Zhou S; Meng Y; Cheng L
Acta Biomater; 2016 Jun; 37():143-54. PubMed ID: 27071973
[TBL] [Abstract][Full Text] [Related]
5. Subconjunctival therapy by cubic liquid crystalline nanoparticles to deliver Triamcinolone acetonide for the management of diabetic Retinopathy: In vivo evidences.
Sharadha M; Vishal Gupta N; Rahamathulla M; Muqtader Ahmed M; Ayesha Farhana S; Osmani RAM; Veeranna B; Koteshwara KB
Int J Pharm; 2023 Nov; 646():123443. PubMed ID: 37748633
[TBL] [Abstract][Full Text] [Related]
6. Triamcinolone acetonide-chitosan coated liposomes efficiently treated retinal edema as eye drops.
Cheng T; Li J; Cheng Y; Zhang X; Qu Y
Exp Eye Res; 2019 Nov; 188():107805. PubMed ID: 31526807
[TBL] [Abstract][Full Text] [Related]
7. Characterization and Pharmacokinetics of Triamcinolone Acetonide-Loaded Liposomes Topical Formulations for Vitreoretinal Drug Delivery.
Altamirano-Vallejo JC; Navarro-Partida J; Gonzalez-De la Rosa A; Hsiao JH; Olguín-Gutierrez JS; Gonzalez-Villegas AC; Keller BC; Bouzo-Lopez L; Santos A
J Ocul Pharmacol Ther; 2018 Jun; 34(5):416-425. PubMed ID: 29584529
[TBL] [Abstract][Full Text] [Related]
8. A more efficient ocular delivery system of triamcinolone acetonide as eye drop to the posterior segment of the eye.
Li J; Cheng T; Tian Q; Cheng Y; Zhao L; Zhang X; Qu Y
Drug Deliv; 2019 Dec; 26(1):188-198. PubMed ID: 30835587
[TBL] [Abstract][Full Text] [Related]
9. A non-invasive nanoparticle-based sustained dual-drug delivery system as an eyedrop for endophthalmitis.
Mahaling B; Baruah N; Ahamad N; Maisha N; Lavik E; Katti DS
Int J Pharm; 2021 Sep; 606():120900. PubMed ID: 34293472
[TBL] [Abstract][Full Text] [Related]
10. Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model.
Chen M; Li X; Liu J; Han Y; Cheng L
J Control Release; 2015 Apr; 203():109-17. PubMed ID: 25700623
[TBL] [Abstract][Full Text] [Related]
11. Polymeric micelles for the ocular delivery of triamcinolone acetonide: preparation and
Safwat MA; Mansour HF; Hussein AK; Abdelwahab S; Soliman GM
Drug Deliv; 2020 Dec; 27(1):1115-1124. PubMed ID: 32720545
[TBL] [Abstract][Full Text] [Related]
12. Effects of shell thickness of hollow poly(lactic acid) nanoparticles on sustained drug delivery for pharmacological treatment of glaucoma.
Nguyen DD; Luo LJ; Lai JY
Acta Biomater; 2020 Jul; 111():302-315. PubMed ID: 32428681
[TBL] [Abstract][Full Text] [Related]
13. Improved release of triamcinolone acetonide from medicated soft contact lenses loaded with drug nanosuspensions.
García-Millán E; Quintáns-Carballo M; Otero-Espinar FJ
Int J Pharm; 2017 Jun; 525(1):226-236. PubMed ID: 28412447
[TBL] [Abstract][Full Text] [Related]
14. Effect of intraocular pressure (IOP) and choroidal circulation on controlled episcleral drug delivery to retina/vitreous.
Li J; Lan B; Li X; Sun S; Lu P; Cheng L
J Control Release; 2016 Dec; 243():78-85. PubMed ID: 27717742
[TBL] [Abstract][Full Text] [Related]
15. Triamcinolone and intraocular sustained-release delivery systems in diabetic retinopathy.
Yilmaz T; Cordero-Coma M; Lavaque AJ; Gallagher MJ; Padula WV
Curr Pharm Biotechnol; 2011 Mar; 12(3):337-46. PubMed ID: 20939800
[TBL] [Abstract][Full Text] [Related]
16. Controlled non-invasive iontophoretic delivery of triamcinolone acetonide amino acid ester prodrugs into the posterior segment of the eye.
Santer V; Chen Y; Kalia YN
Eur J Pharm Biopharm; 2018 Nov; 132():157-167. PubMed ID: 30266666
[TBL] [Abstract][Full Text] [Related]
17. Dendrimer-Triamcinolone Acetonide Reduces Neuroinflammation, Pathological Angiogenesis, and Neuroretinal Dysfunction in Ischemic Retinopathy.
Cho H; Kambhampati SP; Lai MJ; Zhou L; Lee G; Xie Y; Hui Q; Kannan RM; Duh EJ
Adv Ther (Weinh); 2021 Feb; 4(2):. PubMed ID: 34527806
[TBL] [Abstract][Full Text] [Related]
18. Posterior sub-Tenon's capsule injection of triamcinolone acetonide prevents panretinal photocoagulation-induced visual dysfunction in patients with severe diabetic retinopathy and good vision.
Shimura M; Yasuda K; Shiono T
Ophthalmology; 2006 Mar; 113(3):381-7. PubMed ID: 16458970
[TBL] [Abstract][Full Text] [Related]
19. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases.
Babizhayev MA; Kasus-Jacobi A
Curr Clin Pharmacol; 2009 Jan; 4(1):4-37. PubMed ID: 19149498
[TBL] [Abstract][Full Text] [Related]
20. [Survey of triamcinolone acetonide for ocular diseases in Japan].
Sakamoto T; Hida T; Tano Y; Negi A; Takeuchi S; Ishibashi T; Inoue Y; Ohguro N; Okada AA;
Nippon Ganka Gakkai Zasshi; 2007 Dec; 111(12):936-45. PubMed ID: 18186215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
